Eco Animal Health Gp - Posting of Annual Report and Notice of AGM

ECO Animal Health

05/08/2026 11:32

RNS Number : 4206P
  
Eco Animal Health Group PLC
  
05 August 2026
  
 


5 August 2026
 
ECO Animal Health Group plc
("ECO" or the "Company")
 
Posting of Annual Report and Notice of AGM
ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that its Annual Report and Accounts for the year ended 31 March 2026 ("Annual Report"), Notice of Annual General Meeting ("AGM") and Form of Proxy have been posted to shareholders who have elected to receive hard copies by post.
The Company will hold its AGM at the offices of Singer Capital Markets, 1 Bartholomew Lane, London, EC2N 2AX on Tuesday 8 September 2026 at 09.30am BST.
The Annual Report, Notice of AGM and Form of Proxy will be made available on the Company's website at https://ecoanimalhealth.com/investors/.
-Ends-
For further information please contact:








 
ECO Animal Health Group plc
David Hallas (Chief Executive Officer)
Christopher Wilks (Chief Financial Officer)
 




020 8447 8899




ICR Healthcare (Financial PR)
Mary-Jane Elliott
Jessica Hodgson
 


020 3709 5700
 




Singer Capital Markets (Nominated Adviser & Joint Broker)
Jen Boorer
Sara Hale
James Fischer
 


020 7496 3000




Panmure Liberum (Joint Broker)
Emma Earl
Will Goode
Mark Rogers
Rupert Dearden
 


020 3100 2000 
 




Equity Development
Hannah Crowe
Matt Evans


020 7065 2692







 




About ECO Animal Health
 
ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.
 
The Group's proprietary lead product, Aivlosin® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.
 
ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO's pipeline, ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in June 2026.
 
Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.
 
View the Group's website or LinkedIn page for further information.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NOAAKPBNKBKDKFK